{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:46:25Z","timestamp":1787010385354,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Potential kidney donors with active hepatitis B virus (HBV: positive hepatitis B surface antigen [HBsAg] and\/or nucleic acid test [NAT]) are usually declined for HBsAg-negative recipients. Safety may be improved by recipient vaccination and\/or antivirals, thereby increasing transplantation opportunities. We quantified HBV transmission risk in this setting to inform donation decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis (MEDLINE, to November 2024) of cohorts comprised of kidney donors with active HBV intentionally used for HBsAg-negative recipients. Transmission was defined as new HBsAg or NAT positivity posttransplant. Transmission proportions and exact 95% confidence intervals (CIs) were pooled using generalized linear mixed models with logistic transformation and random effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      We included 20 cohorts involving 600 HBsAg-negative recipients from donors with active HBV. Most donors were living (52%), with negative NAT (60%). Most recipients had positive surface antibody (&gt;10 IU\/L, 86%); many were core antibody positive (47%). Antiviral prophylaxis was given to 49% recipients, varying in type, duration, and strategy. There were 29 of 600 HBV transmissions, mostly transient low-level viremia only (62%). The pooled transmission rate was 4.0% (95% CI, 1.8%-8.3%) with low heterogeneity (\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u20050%) but some between-study variance (Tau\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u20051.21). Transmission rates were higher where all donors had positive NAT (16.0%; 95% CI, 10.2%-24.3%), and lower where all recipients were living (0.8%; 95% CI, 0.1%-6.4%) or had positive surface antibody (1.4%; 95% CI, 0.2%-8.8%). Three deaths because of HBV transmissions occurred, all among recipients not taking posttransplant antiviral prophylaxis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Given low transmission rates and mitigating strategies, kidney transplantation may be considered from donors with active HBV, with donor\/recipient risk stratification, consent, and monitoring\/prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005575","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T15:01:47Z","timestamp":1766415707000},"page":"e912-e922","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Transmission Risk of Intentional Transplantation of Kidneys From Donors With Active Hepatitis B to Recipients Without Active Hepatitis B: A Systematic Review and Meta-Analysis"],"prefix":"10.1097","volume":"110","author":[{"given":"Karen M.J.","family":"Waller","sequence":"first","affiliation":[{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."},{"name":"Department of Gastroenterology and Hepatology, Concord Repatriation General Hospital, Concord, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"De La Mata","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Hedley","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trishala","family":"Sharma","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Davies","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Garrett","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"White","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Rawlinson","sequence":"additional","affiliation":[{"name":"Serology and Virology Division (SAViD), NSW Health Pathology Randwick Prince of Wales Hospital, Sydney, NSW, Australia."},{"name":"Schools of SBMS, BABS and Women\u2019s and Children\u2019s, Faculty of Medicine and Health, University of NSW, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Stelzer-Braid","sequence":"additional","affiliation":[{"name":"Serology and Virology Division (SAViD), NSW Health Pathology Randwick Prince of Wales Hospital, Sydney, NSW, Australia."},{"name":"Schools of SBMS, BABS and Women\u2019s and Children\u2019s, Faculty of Medicine and Health, University of NSW, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Wyburn","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."},{"name":"Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C.","family":"Webster","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."},{"name":"Westmead Applied Research Centre, University of Sydney, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"R1-20260521","doi-asserted-by":"crossref","first-page":"e18282","DOI":"10.2196\/18282","article-title":"Safety and Biovigilance in Organ Donation (SAFEBOD): protocol for a population-based cohort study.","volume":"9","author":"Rosales","year":"2020","journal-title":"JMIR Res Protoc"},{"key":"R2-20260521","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/j.kint.2022.07.013","article-title":"KDIGO 2022 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease.","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"R4-20260521","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B.","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"R6-20260521","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/ajt.13187","article-title":"Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management\/\u2020.","volume":"15","author":"Huprikar","year":"2015","journal-title":"Am J Transplant"},{"key":"R7-20260521","doi-asserted-by":"crossref","first-page":"e0117275","DOI":"10.1371\/journal.pone.0117275","article-title":"Investigation of occult hepatitis B virus infection in anti-HBc positive patients from a liver clinic.","volume":"10","author":"Martinez","year":"2015","journal-title":"PLoS One"},{"key":"R8-20260521","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.12659\/MSM.896048","article-title":"Kidney transplantation from donors with hepatitis B.","volume":"22","author":"Veroux","year":"2016","journal-title":"Med Sci Monit"},{"key":"R10-20260521","first-page":"33","article-title":"Hepatitis B virus infection and organ transplantation.","volume":"14","author":"Ayoub","year":"2018","journal-title":"Gastroenterol Hepatol (N. Y)"},{"key":"R11-20260521","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/SLA.0000000000005071","article-title":"Expanding the donor pool: first use of hepatitis b virus Nat positive solid organ allografts into seronegative recipients.","volume":"274","author":"Delman","year":"2021","journal-title":"Ann Surg"},{"key":"R12-20260521","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12879-020-05704-1","article-title":"Pre-transplant donor HBV DNA+ and male recipient are independent risk factors for treatment failure in HBsAg+ donors to HBsAg-kidney transplant recipients.","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R13-20260521","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1111\/liv.15703","article-title":"Expanding the donor pool: kidney transplantation from serum HBV DNA or HBeAg-positive donors to HBsAg-negative recipients.","volume":"43","author":"Yin","year":"2023","journal-title":"Liver Int"},{"key":"R14-20260521","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/tid.12094","article-title":"Renal transplantation from hepatitis B surface antigen (HBsAg)-positive donors to HBsAg-negative recipients: a case of post-transplant fulminant hepatitis associated with an extensively mutated hepatitis B virus strain and review of the current literature.","volume":"15","author":"Magiorkinis","year":"2013","journal-title":"Transplant Infect Dis"},{"key":"R15-20260521","doi-asserted-by":"crossref","first-page":"685298","DOI":"10.3389\/frai.2021.685298","article-title":"Sysrev: a FAIR platform for data curation and systematic evidence review.","volume":"4","author":"Bozada","year":"2021","journal-title":"Front Artif Intell"},{"key":"R17-20260521","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jrsm.1348","article-title":"Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions.","volume":"10","author":"Schwarzer","year":"2019","journal-title":"Res Synth Methods"},{"key":"R18-20260521","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/jrsm.1547","article-title":"Meta-analysis of prevalence: statistic and how to deal with heterogeneity.","volume":"13","author":"Migliavaca","year":"2022","journal-title":"Research Synth Methods"},{"key":"R19-20260521","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12874-021-01381-z","article-title":"Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence.","volume":"21","author":"Barker","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"R20-20260521","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/bmj.297.6652.854-a","article-title":"Renal transplantation from HBsAg positive donors to HBsAg negative recipients.","volume":"297","author":"al-Khader","year":"1988","journal-title":"BMJ"},{"key":"R21-20260521","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00007890-199201000-00025","article-title":"The impact of donor and recipient hepatitis B surface antigen status on liver disease and survival in renal transplant recipients.","volume":"53","author":"Chan","year":"1992","journal-title":"Transplantation"},{"key":"R22-20260521","first-page":"1725","article-title":"Follow-up of renal allograft recipients from HBsAg positive donors. GCIF.","volume":"27","author":"Antoine","year":"1995","journal-title":"Transplant Proc"},{"key":"R23-20260521","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1016\/S0041-1345(97)00929-9","article-title":"Renal transplantation using hepatitis B or C serology-positive donors.","volume":"29","author":"Santos","year":"1997","journal-title":"Transplant Proc"},{"key":"R24-20260521","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1399-0012.2005.00350.x","article-title":"Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas transplantation.","volume":"19","author":"Akalin","year":"2005","journal-title":"Clin Transplant"},{"key":"R25-20260521","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1016\/j.transproceed.2005.10.094","article-title":"The effect of HBsAg-positivity of kidney donors on long-term patient and graft outcome.","volume":"37","author":"Berber","year":"2005","journal-title":"Transplant Proc"},{"key":"R26-20260521","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.transproceed.2008.07.078","article-title":"HBsAg(+) donor as a kidney transplantation deceased donor.","volume":"40","author":"Wei","year":"2008","journal-title":"Transplant Proc"},{"key":"R27-20260521","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/j.1600-6143.2009.02707.x","article-title":"Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center.","volume":"9","author":"Jiang","year":"2009","journal-title":"Am J Transplant"},{"key":"R28-20260521","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.transproceed.2008.09.056","article-title":"Ten-year follow-up of kidney transplantation from hepatitis B surface antigen-positive donors.","volume":"41","author":"Sumethkul","year":"2009","journal-title":"Transplant Proc"},{"key":"R29-20260521","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.transproceed.2012.04.028","article-title":"Use of kidney donors with hepatitis B, hepatitis C, or brain tumor: a single-center experience.","volume":"44","author":"Tatar","year":"2012","journal-title":"Transplant Proc"},{"key":"R30-20260521","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.transproceed.2013.02.058","article-title":"Kidney transplantation from hepatitis B (HB)-positive donors to HB negative recipients: anti-HB core immunoglobulin G became positive in all recipients after the transplantation.","volume":"45","author":"Celebi","year":"2013","journal-title":"Transplant Proc"},{"key":"R31-20260521","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/ajt.12921","article-title":"The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg)-negative recipients receiving graft from HBsAg-positive donors: a retrospective, propensity score-matched study.","volume":"14","author":"Chancharoenthana","year":"2014","journal-title":"Am J Transplant"},{"key":"R32-20260521","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00007890-201407151-00444","article-title":"Living donor kidney transplantation from HBsAg(+) donor to HBsAg(-) recipient with or without anti-HBs. Abstract# 2916.","volume":"98","author":"Kong","year":"2014","journal-title":"Transplantation"},{"key":"R33-20260521","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.transproceed.2015.04.014","article-title":"Donors with hepatitis B surface antigen positivity.","volume":"47","author":"Asuman Yavuz","year":"2015","journal-title":"Transplant Proc"},{"key":"R34-20260521","doi-asserted-by":"crossref","first-page":"390","DOI":"10.12659\/AOT.894073","article-title":"Assessment of long-term outcomes in Hbs Ag-negative renal transplant recipients transplanted from Hbs Ag-positive donors.","volume":"20","author":"Yilmaz","year":"2015","journal-title":"Ann Transplant"},{"key":"R35-20260521","doi-asserted-by":"crossref","first-page":"e13872","DOI":"10.1111\/tid.13872","article-title":"Use of hepatitis B viremic donors in kidney transplant recipients: a single center experience.","volume":"24","author":"Carnemolla","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"R36-20260521","doi-asserted-by":"crossref","first-page":"e14295","DOI":"10.1111\/tid.14295","article-title":"Utilization of hepatitis B viremic donors (NAT+) leads to improved kidney transplant access for older adult recipients with little to no wait time.","volume":"26","author":"Lopez-Soler","year":"2024","journal-title":"Transplant Infect Dis"},{"key":"R37-20260521","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","article-title":"KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation.","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"key":"R38-20260521","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3390\/idr13040094","article-title":"Hepatitis B vaccination in advanced chronic kidney disease: a quality improvement project at a veteran affairs chronic kidney disease clinic.","volume":"13","author":"Hettenbaugh","year":"2021","journal-title":"Infect Dis Rep"},{"key":"R39-20260521","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcv.2015.04.011","article-title":"Considerable decrease in antibodies against hepatitis B surface antigen following kidney transplantation.","volume":"68","author":"Moal","year":"2015","journal-title":"J Clin Virol"},{"key":"R40-20260521","doi-asserted-by":"crossref","first-page":"ofy342","DOI":"10.1093\/ofid\/ofy342","article-title":"Durability of antibody response against the hepatitis B virus in kidney transplant recipients: a proposed immunization guideline from a 3-year follow-up clinical study.","volume":"6","author":"Chancharoenthana","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"R42-20260521","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1111\/ajt.15886","article-title":"Hepatitis B surface antigen\u2013positive donor to negative recipient lung transplantation.","volume":"20","author":"Belga","year":"2020","journal-title":"Am J Transplant"},{"key":"R44-20260521","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/lt.26543","article-title":"Use and outcomes of hepatitis B virus-positive grafts in orthotopic liver transplantation in the United States from 1999 to 2021.","volume":"29","author":"Ali","year":"2023","journal-title":"Liver Transpl"},{"key":"R45-20260521","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1007\/s11605-020-04759-4","article-title":"Cost-effectiveness of utilization of hepatitis B virus-positive liver donors for HBV-negative transplant recipients.","volume":"25","author":"Lee","year":"2021","journal-title":"J Gastrointest Surg"},{"key":"R46-20260521","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/jvh.12972","article-title":"Long-term outcome and recurrence of hepatitis B virus following liver transplantation from hepatitis B surface antigen-positive donors in a Chinese population.","volume":"25","author":"Wei","year":"2018","journal-title":"J Viral Hepat"},{"key":"R47-20260521","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/TP.0000000000004759","article-title":"Use and outcomes of hepatitis B virus-positive grafts for kidney or heart transplantation in the United States from 1999 to 2021.","volume":"108","author":"Singal","year":"2024","journal-title":"Transplantation"},{"key":"R48-20260521","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/TP.0b013e31824e3db4","article-title":"Hepatitis B\u2013positive donors in renal transplantation: increasing the deceased donor pool.","volume":"94","author":"Pilmore","year":"2012","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:00:12Z","timestamp":1779382812000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005575","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}